FOR US HEALTHCARE PROFESSIONALS ONLY

FOR US HEALTHCARE PROFESSIONALS ONLY

REQUEST A REP

Phase 3 trial

DUVYZAT was studied in EPIDYS, one of the most inclusive phase 3 DMD studies to date1,*

EPIDYS was a global, 18-month, double-blind, randomized, placebo-controlled trial (N=179).1,2

Ethan, an actual Duvyzat® (givinostat) patient

Ethan, actual DUVYZAT patient for 5+ years.

Patient population:
  • Ambulant boys aged ≥6 years with genetically confirmed DMD who were receiving a stable corticosteroid regimen (median age of 9.8 years)1,2
  • All patients completed two 4SC assessments (mean of ≤8 seconds) and a time-to-rise assessment (≥3 but <10 seconds)1
  • No restrictions on genetic mutations, but these were generally balanced across both groups1

Efficacy was assessed in 120 patients using multiple measures, including 4SC,† NSAA (including time-to-rise from the floor), 6-minute walk test, change in VLFF, and a muscle strength assessment (knee extension and elbow flexion).1

Safety was assessed in 179 patients (Group A + Group B).1

Recruitment was prespecified in 2 groups1:

Efficacy and safety analysis, n=120

  • Baseline VLFF >5% but ≤30%
  • Unlikely to lose mobility abruptly but expected to show measurable decline in function, strength, and fat fraction on placebo + corticosteroids

Safety analysis only, n=59

  • Baseline VLFF ≤5% or >30%
  • Recruited to assess the safety of DUVYZAT + corticosteroids in a broader population of patients with DMD

4SC, 4-stair climb; DMD, Duchenne muscular dystrophy; NSAA, North Star Ambulatory Assessment; VLFF, vastus lateralis fat fraction.

* EPIDYS is an acronym for Epigenetic Rescue of Dystrophin Dysfunction trial.1

† 4SC is a measure of muscle function that tests the time it takes to climb 4 stairs.2

Ethan, an actual Duvyzat® (givinostat) patient

Ethan, actual DUVYZAT patient for 5+ years.

4-STAIR CLIMB
NSAA
VLFF

PRIMARY ENDPOINT: 4SC

PROVEN PROTECTION against DMD progression with DUVYZAT2

Patients treated with DUVYZAT were able to complete 4SC faster than patients taking placebo2

Change in time to perform 4SC vs placebo2

Estimates compared across multiple real-world and clinical trial data sources indicate that change ≥1.3 seconds to complete 4SC may be clinically meaningful.3

KEY SECONDARY ENDPOINT: NSAA

DUVYZAT demonstrated greater preservation of motor function vs placebo as shown by NSAA1,§

Change from baseline in total NSAA item score over 18 months1,||

§ Nominally significant but not statistically significant based on prespecified multiplicity adjustment.1

II NSAA is a DMD-specific assessment scale measuring lower limb function in ambulant children with DMD comprising 17 items scored on a scale of 0 to 2. A score of 2 indicates the activity is performed without difficulty, 1 indicates the activity is performed with some compensation, and 0 indicates the activity cannot be performed independently.1,2,5

KEY SECONDARY ENDPOINT: VLFF

Compared with placebo at 18 months,

DUVYZAT reduced new fat infiltration in key muscle groups required for ambulation1,2,6,7,§

Change in mean VLFF over 18 months from baseline1,6

At 18 months, for patients with baseline VLFF in the range of >5% to ≤30%, mean increase (absolute difference from baseline) in VLFF was 7.48% in DUVYZAT-treated patients compared to 10.89% in patients who received placebo.2

§ Nominally significant but not statistically significant based on prespecified multiplicity adjustment.1

EXPLORATORY ANALYSIS: VLFF

DUVYZAT reduced new fat infiltration in the thigh muscle1,2,6

Baseline
18 months
MRS imaging of thigh muscle - Baseline
MRS imaging of thigh muscle - Patient taking placebo 18 months
Patient taking placebo + corticosteroids
MRS imaging of thigh muscle - Patient taking DUVYZAT® (givinostat) baseline
MRS imaging of thigh muscle - Patient taking DUVYZAT® (givinostat) 18 months
Patient taking DUVYZAT + corticosteroids
Baseline
18 months

MRS images showing VLFF increase from baseline after 18 months.1

Images are from single individuals and may not be representative of all patients' results.

MRS, magnetic resonance spectroscopy.

DUVYZAT safety

DUVYZAT safety is based on the pivotal EPIDYS 18-month study in a total of 179 ambulant patients with DMD aged 6 years and older on concomitant corticosteroid treatment.2

Adverse reactions reported in >5% of DUVYZAT-treated patients2

Adverse reaction, % DUVYZAT + corticosteroids (n=118) Placebo + corticosteroids (n=61)
Diarrhea 37 20
Abdominal pain 34 25
Thrombocytopenia‡ 33 0
Nausea/vomiting 32 18
Hypertriglyceridemia 23 7
Pyrexia 13 8
Myalgia 9 3
Rash 9 2
Arthralgia 8 2
Fatigue 8 0
Constipation 7 2
Decreased appetite 7 0
  • Diarrhea, the most common adverse reaction, usually occurred within the first few weeks of treatment and resolved with continued dosing2,4
    • Antiemetics or antidiarrheal medications may be considered during treatment with DUVYZAT. Fluid and electrolytes should be replaced as needed to prevent dehydration2

‡ Thrombocytopenia includes platelet count decreased and thrombocytopenia.

95% of patients completed the EPIDYS clinical trial.1

Get started with DUVYZAT

Download and complete this form to get your patients started with DUVYZAT with the help of ITF ARC. ACCESS THE FORM

Sign up for updates

Get valuable resources, patient support tools, and information delivered directly to you. SIGN UP

References: 1. Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al; EPIDYS Study Group. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23(4):393-403. 2. DUVYZAT. Prescribing information. ITF Therapeutics; 2024. 3. Muntoni F, Signorovitch J, Sajeev G, et al. Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): a multi-center study. PLoS One. 2024;19(7):e0304984. 4. Data on file. ITF Therapeutics; 2025. 5. Ayyar Gupta V, Pitchforth JM, Domingos J, et al. Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy. PLoS One. 2023;18(4):e0283669. 6. Vandenborne K. Givinostat in DMD: results of the Epidys study with particular attention to MR measures of muscle fat fraction. Oral presentation at: Muscular Dystrophy Association Clinical & Scientific Conference; March 19-22, 2023; Dallas, TX. 7. Liu MQ, Anderson FC, Schwartz MH, Delp SL. Muscle contributions to support and progression over a range of walking speeds. J Biomech. 2008;41(15):3243-3252.

More than 2000 people with DMD have been prescribed DUVYZAT.2,† †Includes global patients (US and EU participants).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Hematological Changes: DUVYZAT can cause dose-related thrombocytopenia and other signs of myelosuppression. Monitor blood count every 2 weeks for the first 2 months, at month 3, and every 3 months thereafter. Modify the dosage for confirmed thrombocytopenia. Discontinuation may be needed if abnormalities worsen.
  • Increased Triglycerides: DUVYZAT can cause elevations in triglycerides. Monitor triglycerides at 1 month, 3 months, 6 months, and then every 6 months thereafter. Modify the dosage if fasting triglycerides are verified >300 mg/dL. Treatment with DUVYZAT should be discontinued if triglycerides remain elevated despite adequate dietary intervention and dosage adjustment.
  • Gastrointestinal Disturbances: Gastrointestinal disturbances, including diarrhea, nausea/vomiting, and abdominal pain were common adverse reactions in DUVYZAT clinical trials. Antiemetics or antidiarrheal medications may be considered during treatment with DUVYZAT. Modify the dosage of DUVYZAT in patients with moderate or severe diarrhea and discontinue treatment if significant symptoms persist.
  • QTc Prolongation: DUVYZAT can cause prolongation of the QTc interval. Avoid use of DUVYZAT in patients who are at an increased risk for ventricular arrhythmias (including torsades de pointes), such as those with congenital long QT syndrome, coronary artery disease, electrolyte disturbance or in patients taking concomitant medicinal products known to cause QT prolongation. Obtain ECGs prior to initiating treatment with DUVYZAT in patients with underlying cardiac disease or in patients who are taking concomitant medications that cause QT prolongation.

Adverse Reactions

The most common adverse reactions reported in >5% of patients treated with DUVYZAT are diarrhea (37%), abdominal pain (34%), thrombocytopenia (33%), nausea/vomiting (32%), hypertriglyceridemia (23%), pyrexia (13%), myalgia (9%), rash (9%), arthralgia (8%), fatigue (8%), constipation (7%), and decreased appetite (7%).

Drug Interactions

Closely monitor when DUVYZAT is used in combination with an oral CYP3A4 sensitive substrate or a sensitive substrate of the OCT2 transporter, for which a small change in substrate plasma concentrations may lead to serious toxicities.

Avoid concomitant use with other drugs that prolong the QTc interval; monitor ECG if concomitant use cannot be avoided. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold DUVYZAT if the QTc interval is >500 ms or the change from baseline is >60 ms.

INDICATION

DUVYZAT is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.

To report SUSPECTED ADVERSE REACTIONS, contact ITF Therapeutics LLC at 1-833-582-4312 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for additional safety information.

More than 2000 people with DMD have been prescribed DUVYZAT.2,† †Includes global patients (US and EU participants).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Hematological Changes: DUVYZAT can cause dose-related thrombocytopenia and other signs of myelosuppression. Monitor blood count every 2 weeks for the first 2 months, at month 3, and every 3 months thereafter. Modify the dosage for confirmed thrombocytopenia. Discontinuation may be needed if abnormalities worsen.
  • Increased Triglycerides: DUVYZAT can cause elevations in triglycerides. Monitor triglycerides at 1 month, 3 months, 6 months, and then every 6 months thereafter. Modify the dosage if fasting triglycerides are verified >300 mg/dL. Treatment with DUVYZAT should be discontinued if triglycerides remain elevated despite adequate dietary intervention and dosage adjustment.
  • Gastrointestinal Disturbances: Gastrointestinal disturbances, including diarrhea, nausea/vomiting, and abdominal pain were common adverse reactions in DUVYZAT clinical trials. Antiemetics or antidiarrheal medications may be considered during treatment with DUVYZAT. Modify the dosage of DUVYZAT in patients with moderate or severe diarrhea and discontinue treatment if significant symptoms persist.
  • QTc Prolongation: DUVYZAT can cause prolongation of the QTc interval. Avoid use of DUVYZAT in patients who are at an increased risk for ventricular arrhythmias (including torsades de pointes), such as those with congenital long QT syndrome, coronary artery disease, electrolyte disturbance or in patients taking concomitant medicinal products known to cause QT prolongation. Obtain ECGs prior to initiating treatment with DUVYZAT in patients with underlying cardiac disease or in patients who are taking concomitant medications that cause QT prolongation.

Adverse Reactions

The most common adverse reactions reported in >5% of patients treated with DUVYZAT are diarrhea (37%), abdominal pain (34%), thrombocytopenia (33%), nausea/vomiting (32%), hypertriglyceridemia (23%), pyrexia (13%), myalgia (9%), rash (9%), arthralgia (8%), fatigue (8%), constipation (7%), and decreased appetite (7%).

Drug Interactions

Closely monitor when DUVYZAT is used in combination with an oral CYP3A4 sensitive substrate or a sensitive substrate of the OCT2 transporter, for which a small change in substrate plasma concentrations may lead to serious toxicities.

Avoid concomitant use with other drugs that prolong the QTc interval; monitor ECG if concomitant use cannot be avoided. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold DUVYZAT if the QTc interval is >500 ms or the change from baseline is >60 ms.

INDICATION

DUVYZAT is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.

To report SUSPECTED ADVERSE REACTIONS, contact ITF Therapeutics LLC at 1-833-582-4312 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for additional safety information.